Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer.
OBJECTIVE
To observe the dynamic changes of blood perfusion and hypoxic status with CT perfusion imaging and hypoxia imaging in patients of non-small-cell lung cancer (NSCLC) who were treated with recombinant human endostatin (RHES).


METHODS
Fifteen previously untreated patients with histologically or cytologically confirmed NSCLC were enrolled. They were randomly divided into research group (n=10) and negative control group (n=5). The patients of the research group continuously used RHES for ten days, and simultaneously had CT perfusion imaging and hypoxia imaging performed on days 1, 5 and 10, respectively. The remaining 5(control) only had CT perfusion imaging and hypoxia imaging, without using RHES, on days 1, 5 and 10, respectively. According to the above results, we could obtain a "time window" during which RHES improves blood perfusion and hypoxia of lung cancer.


RESULTS
In the research group, after using RHES, capillary permeability surface (PS) and tumour to normal tissue (T/N) decreased at first, and then increased. Their lowest points occurred on about the fifth day with statistical significance compared with the first day (T/N, p=0.00; PS, p<0.01). Blood flow (BF) was first increased and then decreased. Its highest point occurred on about the fifth day with statistical significance compared with the first and tenth day (all p<0.01). The PS, BF and T/N peaked on the fifth day in the research group with statistical significance compared with the negative control group as well (all p<0.01). The above results suggested that RHES's "time window" was within about one week after administration.


CONCLUSIONS
RHES's "time window" is within about one week after administration, which provides an important experimental basis for combining RHES with radiotherapy in human tumours.
Department of Oncology, Lianyungang First People's Hospital, Lianyungang 222002, China. jxdysy@sohu.com
Xiao-Dong
XD
Jiang
Peng
P
Dai
Yun
Y
Qiao
Jin
J
Wu
Da-An
DA
Song
Shi-Qiu
SQ
Li
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D015687:Cell Hypoxia; D043169:Endostatins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply* / Q000473:pathology / Q000628:therapy; D008297:Male; D055420:Perfusion Imaging; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D036542:Tomography, Spiral Computed
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D011994:Recombinant Proteins